- Stocks
- Healthcare
- NYSE: ABBV

Price (delayed)

$110.86

Market cap

$195.72B

P/E Ratio

23.34

Dividend/share

$4.84

EPS

$4.75

Enterprise value

$274.89B

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate

The company's net income has surged by 127% YoY and by 6% QoQ

The EPS has soared by 109% YoY

The quick ratio has contracted by 26% YoY but it has grown by 17% from the previous quarter

The debt has surged by 127% year-on-year

ABBV's P/E is 35% above its last 4 quarters average of 17.3 and 12% above its 5-year quarterly average of 20.9

What are the main financial stats of ABBV

Market
Valuations
Earnings

Shares outstanding

1.77B

Market cap

$195.72B

Enterprise value

$274.89B

Price to earnings (P/E)

23.34

Price to book (P/B)

12.81

Price to sales (P/S)

4.82

EV/EBIT

27.24

EV/EBITDA

18.32

EV/Sales

6.76

Revenue

$40.65B

EBIT

$10.09B

EBITDA

$15.01B

Free cash flow

$15.33B

Per share
Balance sheet
Liquidity

EPS

$4.75

Free cash flow per share

$8.66

Book value per share

$8.65

Revenue per share

$22.98

TBVPS

$18.19

Total assets

$149.62B

Total liabilities

$134.33B

Debt

$87.06B

Equity

$15.27B

Working capital

-$1.17B

Debt to equity

5.7

Current ratio

0.95

Quick ratio

0.68

Net debt/EBITDA

5.28

Margins
Efficiency
Dividend

EBITDA margin

36.9%

Gross margin

68.7%

Net margin

18.2%

Operating margin

28.5%

Return on assets

6.2%

Return on equity

205.2%

Return on invested capital

13.1%

Return on capital employed

8%

Return on sales

24.8%

Dividend yield

4.37%

DPS

$4.84

Payout ratio

101.9%

How has the AbbVie stock price performed over time

Intraday

-0.36%

1 week

0.31%

1 month

7.84%

1 year

27.12%

YTD

3.46%

QTD

3.46%

How have AbbVie's revenue and profit performed over time

Revenue

$40.65B

Gross profit

$27.94B

Operating income

$11.57B

Net income

$7.38B

Gross margin

68.7%

Net margin

18.2%

The company's net income has surged by 127% YoY and by 6% QoQ

The net margin has surged by 84% year-on-year but it has declined by 5% since the previous quarter

The operating income has soared by 76% YoY and by 6% from the previous quarter

The operating margin rose by 43% year-on-year but it has declined by 6% since the previous quarter

What is AbbVie's growth rate over time

What is AbbVie stock price valuation

P/E

23.34

P/B

12.81

P/S

4.82

EV/EBIT

27.24

EV/EBITDA

18.32

EV/Sales

6.76

The EPS has soared by 109% YoY

ABBV's P/E is 35% above its last 4 quarters average of 17.3 and 12% above its 5-year quarterly average of 20.9

AbbVie's equity has increased by 3.8% from the previous quarter

ABBV's revenue is up by 24% year-on-year and by 12% since the previous quarter

ABBV's P/S is 24% above its last 4 quarters average of 3.9 and 15% above its 5-year quarterly average of 4.2

How efficient is AbbVie business performance

The ROS has soared by 88% YoY but it has contracted by 4.2% from the previous quarter

AbbVie's return on assets has decreased by 13% QoQ but it has increased by 11% YoY

AbbVie's ROIC has increased by 12% YoY but it has decreased by 11% from the previous quarter

What is ABBV's dividend history

DPS

$4.84

Dividend yield

4.37%

Payout ratio

101.9%

Recent dividends

How did AbbVie financials performed over time

AbbVie's total assets is 11% higher than its total liabilities

The quick ratio has contracted by 26% YoY but it has grown by 17% from the previous quarter

ABBV's current ratio is down by 17% year-on-year but it is up by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.